Adam Maeder
Stock Analyst at Piper Sandler
(3.40)
# 974
Out of 5,150 analysts
102
Total ratings
49.33%
Success rate
4.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXST RxSight | Maintains: Neutral | $11 → $10 | $7.93 | +26.10% | 4 | Feb 26, 2026 | |
| TCMD Tactile Systems Technology | Maintains: Overweight | $35 → $42 | $30.17 | +39.21% | 6 | Feb 18, 2026 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $165 → $85 | $64.32 | +32.15% | 18 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Overweight | $98 → $100 | $85.22 | +17.34% | 19 | Feb 11, 2026 | |
| RMD ResMed | Maintains: Neutral | $270 → $275 | $259.05 | +6.16% | 5 | Jan 30, 2026 | |
| ISRG Intuitive Surgical | Maintains: Overweight | $610 → $620 | $501.18 | +23.71% | 22 | Jan 23, 2026 | |
| ABT Abbott Laboratories | Maintains: Overweight | $150 → $135 | $113.10 | +19.36% | 4 | Jan 23, 2026 | |
| SGHT Sight Sciences | Upgrades: Overweight | $5 → $9 | $5.41 | +66.36% | 3 | Jan 5, 2026 | |
| NYXH Nyxoah | Reiterates: Overweight | $12 → $9 | $3.94 | +128.43% | 9 | Nov 14, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $1.61 | +148.45% | 4 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $19.21 | +9.32% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $1.33 | +501.50% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.20 | +127.27% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $65.26 | +51.70% | 3 | May 5, 2022 |
RxSight
Feb 26, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $7.93
Upside: +26.10%
Tactile Systems Technology
Feb 18, 2026
Maintains: Overweight
Price Target: $35 → $42
Current: $30.17
Upside: +39.21%
Inspire Medical Systems
Feb 12, 2026
Maintains: Overweight
Price Target: $165 → $85
Current: $64.32
Upside: +32.15%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Overweight
Price Target: $98 → $100
Current: $85.22
Upside: +17.34%
ResMed
Jan 30, 2026
Maintains: Neutral
Price Target: $270 → $275
Current: $259.05
Upside: +6.16%
Intuitive Surgical
Jan 23, 2026
Maintains: Overweight
Price Target: $610 → $620
Current: $501.18
Upside: +23.71%
Abbott Laboratories
Jan 23, 2026
Maintains: Overweight
Price Target: $150 → $135
Current: $113.10
Upside: +19.36%
Sight Sciences
Jan 5, 2026
Upgrades: Overweight
Price Target: $5 → $9
Current: $5.41
Upside: +66.36%
Nyxoah
Nov 14, 2025
Reiterates: Overweight
Price Target: $12 → $9
Current: $3.94
Upside: +128.43%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $1.61
Upside: +148.45%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $19.21
Upside: +9.32%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $1.33
Upside: +501.50%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.20
Upside: +127.27%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $65.26
Upside: +51.70%